QUTENZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUTENZA (QUTENZA).
QUTENZA (capsaicin) is a transient receptor potential vanilloid 1 (TRPV1) agonist. It selectively binds to TRPV1 receptors on cutaneous nociceptors, causing initial excitation followed by defunctionalization and reduced sensitivity to pain.
| Metabolism | Capsaicin is metabolized primarily by cytochrome P450 enzymes, including CYP2E1, CYP1A2, and CYP3A4, to various metabolites, including vanillyl alcohol and vanillyl aldehyde. |
| Excretion | Primarily renal; capsaicin and metabolites excreted in urine, with <1% unchanged. Fecal elimination accounts for <5%. |
| Half-life | 6.5 hours (range 5-8 hours) for systemic capsaicin; transient due to rapid metabolism. Clinically, local effects persist beyond systemic clearance. |
| Protein binding | Approximately 97% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.4 L/kg, indicating limited distribution into total body water and high tissue binding at site of action. |
| Bioavailability | Topical: minimal systemic absorption (<1% of applied dose); oral: not applicable; intravenous: not used clinically. |
| Onset of Action | Analgesic effect: within 15-30 minutes of patch application, peaking at 1-2 hours post-application. |
| Duration of Action | Up to 12 weeks after a single 60-minute application. Pain relief may require repeated treatments every 3 months. |
Topical patch applied to painful area for 60 minutes every 3 months (up to 4 patches per application).
| Dosage form | PATCH |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment recommended; apply similarly as in younger adults (≥18 years). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QUTENZA (QUTENZA).
| Breastfeeding | Systemic absorption of capsaicin after QUTENZA application is minimal; it is unknown whether capsaicin is excreted in human milk. Due to negligible systemic concentrations, transfer into breast milk is unlikely. However, caution should be exercised when administered to a nursing woman. No M/P ratio is available. |
| Teratogenic Risk | QUTENZA (capsaicin 8% patch) is not absorbed systemically in significant amounts following topical application; systemic concentrations are negligible (<5 ng/mL). Therefore, no fetal exposure is expected. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with the 8% patch. Based on lack of systemic absorption, the risk of teratogenicity is considered low. However, as a precaution, use during pregnancy only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to capsaicin or any component of QUTENZA","Open wounds or broken skin at application site","Severe renal impairment (CrCl <30 mL/min) due to increase in bleeding events with topical NSAIDs if used concurrently (note: QUTENZA is not an NSAID but precaution)","Pregnancy (Category C: risk not ruled out)","Lactation (excretion unknown; caution)"]
| Precautions | ["Severe acute pain during and shortly after application; treatment with local anesthetics or oral analgesics may be needed.","Burn risk due to capsaicin's heat sensation; avoid heat sources on application site.","Orthostatic hypotension in diabetic neuropathy patients.","Peripheral sensory neuropathy progression.","Application site reactions (erythema, rash, pruritus).","Avoid ocular or mucous membrane contact; immediately flush with water.","Use only on intact skin."] |
Loading safety data…
| Fetal Monitoring | Standard prenatal care with no additional specific monitoring required for QUTENZA due to negligible systemic absorption. Monitor for local skin reactions at application site. No fetal monitoring indicated. |
| Fertility Effects | No studies have been conducted on the effects of QUTENZA on fertility. Based on negligible systemic absorption, no impact on fertility is expected. |